Local Perspective on the Practices and Challenges of Migrant Integration: The Case of Warsaw

Poland is currently experiencing a transition with regard to migration trends. Foreign immigration, perceived until recently as a secondary issue by public administration, is on the increase. The largest groups of immigrants have traditionally included Ukrainians and the Vietnamese, although the country has not experienced a significant influx of foreigners arriving from Middle East and African countries. At present, Poland has no migration policy document in force and integrative actions are undertaken mostly by local governments, typically on an ad hoc basis. As Poland’s capital city, Warsaw plays a key role in governing diversity and implementing integrative actions. Significant challenges to immigrant integration include barriers to settlement and discrimination on the labour and housing market, along with a substantial rise in negative attitudes towards foreigners amongst members of Polish society. It is mainly this last aspect that is addressed by Warsaw’s local government, which prioritises educational and awareness-raising measures. It must be acknowledged that this is done in close cooperation with the non-governmental sector, where organisations with expertise in relevant fields are commissioned to perform many tasks. The main challenge of integrative actions at the local level is that these are mostly incoherent measures, which in most cases are not sufficient for the actual needs of immigrants. Hence, it is necessary to develop systemic solutions with sound, long-term financing. Moreover, in order for integration to be successful, it is essential to ensure the coordination of measures taken by public institutions at both central and local government level and to ensure the participation of immigrant communities in the development of public policies

Hyperhomocysteinemia in type 2 diabetic patients - still is considered as a risk factor or it’s only marker of atherosclerosis?

Hiperhomocysteinemia to patologiczne zjawisko wyraźnie wiążące się z rozwojem miażdżycy i schorzeń powstających na jej podłożu, które ma szczególne znaczenie u chorych na cukrzycę typu 2. Mimo to istnieje sporo wątpliwości, czy hiperhomocysteinemię należy traktować jako czynnik ryzyka miażdżycy, czy też jest to tylko marker tego rodzaju zmian. Wyjaśnienie tego problemu miałoby ogromne znaczenie praktyczne i pozwoliłoby sformułować odpowiednie zalecenia terapeutyczne. Niniejsza praca stanowi przegląd najważniejszych danych na temat właściwości biologicznych homocysteiny, przyczyn hiperhomocysteinemii oraz wyników badań dotyczących związków między hiperhomocysteinemią a miażdżycą u chorych na cukrzycę typu 2.Hyperhomocysteinemia is a pathological phenomenon markedly associated with atherosclerosis and atherosclerosis-related diseases development. Patients with diabetes type 2 are especially affected by hiperhomocysteinemia. However, there is quite a lot of doubts if hiperhomocysteinemia should be considered as atherosclerotic risk factor or it’s only marker of atherosclerosis. The elucidation of this problem could be of great practical importance and could allow to express adequate therapeutic recommendations. The manuscript contains the review of the most essential data concerning homocysteine biological properties, the reasons of hyperhomocysteinemia and results of studies focused on the relationship between hyperhomocysteinemia and atherosclerosis in type 2 diabetic patients

The effectiveness of bronchial artery embolisation in patients with haemoptysis

Introduction: Bronchial artery embolisation (BAE) is one of the methods used in massive and recurring haemoptysis. The aim ofthe study is to determine the effectiveness and complications of bronchial artery embolisation in recurring haemoptysis. Material and methods: The analysis included 47 embolisation procedures performed on 30 patients treated between 2011 and2017 in the Department of Respiratory Medicine, Allergology and Pulmonary Oncology due to haemoptysis. The patient’s age rangedbetween 18 and 71 years, while mean age at the time of BAE was 33.5 years. Patients with tuberculosis constituted 73.33% (n = 22)of the sample and underwent 31 embolisation procedures in total. The remaining part of the sample (n = 8) collectively underwent 16BAEs. The analysis was conducted by verifying the medical documentation, as well as carrying face-to-face and phone conversations. Results: Immediate control due to the inhibition of bleeding was obtained in 95.75% of cases. Recurrence within 3 days of BAEwas reported in 5 patients (10.63%), and 4 re-embolisation procedures were conducted. In 10 patients (33.33%), recurrencewas observed during the first year post-BAE, while it was reported in 17 cases during the whole observation period (56.66% ofpatients). The subjects who underwent re-embolisation demonstrated recurrence-free periods lasting from 2 days to 63 months.In patients with recurrence but no re-embolisation, the shortest and longest haemoptysis-free time was 2 and 35 months, respectively.11 patients (36.66%) required several embolisation procedures during the whole observation period. Conclusions: BAE is a highly successful procedure in treating haemoptysis. The risk of complications is low

Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma

Deleted in Liver Cancer (DLC) proteins belong to the family of RhoGAPs and are believed to operate as negative regulators of the Rho family of small GTPases. So far, the role of the first identified member from the DLC family, DLC1, was established as a tumor suppressor in hepatocellular carcinoma. The function of its close family relative, DLC2 is unequivocal. In the present study we attempted to determine whether the loss of DLC2 is a common feature of hepatocellular carcinoma tissue. We examined two types of hepatocellular carcinoma- typical and fibrolamellar one. Our analysis revealed that DLC2 protein is not diminished in cancer tissue when compared to non-cancerous liver specimens. What is more, we observed DLC2 to be more abundantly expressed in cancer tissue, particularly in tumors with the inflammation background. In addition, we found that DLC2 gene status was diploid in virtually all tumor samples examined. Our results indicate that DLC2 is not diminished in hepatocellular carcinoma cells. It appears that members of the DLC family, although structurally highly related, may function differently in cancer cells

Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice

<p>Abstract</p> <p>Background</p> <p>HO-1 participates in the degradation of heme. Its products can exert unique cytoprotective effects. Numerous tumors express high levels of HO-1 indicating that this enzyme might be a potential therapeutic target. In this study we decided to evaluate potential cytostatic/cytotoxic effects of zinc protoporphyrin IX (Zn(II)PPIX), a selective HO-1 inhibitor and to evaluate its antitumor activity in combination with chemotherapeutics.</p> <p>Methods</p> <p>Cytostatic/cytotoxic effects of Zn(II)PPIX were evaluated with crystal violet staining and clonogenic assay. Western blotting was used for the evaluation of protein expression. Flow cytometry was used to evaluate the influence of Zn(II)PPIX on the induction of apoptosis and generation of reactive oxygen species. Knock-down of HO-1 expression was achieved with siRNA. Antitumor effects of Zn(II)PPIX alone or in combination with chemotherapeutics were measured in transplantation tumor models.</p> <p>Results</p> <p>Zn(II)PPIX induced significant accumulation of reactive oxygen species in tumor cells. This effect was partly reversed by administration of exogenous bilirubin. Moreover, Zn(II)PPIX exerted potent cytostatic/cytotoxic effects against human and murine tumor cell lines. Despite a significant time and dose-dependent decrease in cyclin D expression in Zn(II)PPIX-treated cells no accumulation of tumor cells in G1 phase of the cell cycle was observed. However, incubation of C-26 cells with Zn(II)PPIX increased the percentage of cells in sub-G1 phase of the cells cycle. Flow cytometry studies with propidium iodide and annexin V staining as well as detection of cleaved caspase 3 by Western blotting revealed that Zn(II)PPIX can induce apoptosis of tumor cells. B16F10 melanoma cells overexpressing HO-1 and transplanted into syngeneic mice were resistant to either Zn(II)PPIX or antitumor effects of cisplatin. Zn(II)PPIX was unable to potentiate antitumor effects of 5-fluorouracil, cisplatin or doxorubicin in three different tumor models, but significantly potentiated toxicity of 5-FU and cisplatin.</p> <p>Conclusion</p> <p>Inhibition of HO-1 exerts antitumor effects but should not be used to potentiate antitumor effects of cancer chemotherapeutics unless procedures of selective tumor targeting of HO-1 inhibitors are developed.</p

Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma

Burkitt lymphoma is a fast-growing tumor derived from germinal center B cells. It is mainly treated with aggressive chemotherapy, therefore novel therapeutic approaches are needed due to treatment toxicity and developing resistance. Disturbance of red-ox homeostasis has recently emerged as an efficient antitumor strategy. Peroxiredoxins (PRDXs) are thioredoxin-family antioxidant enzymes that scavenge cellular peroxides and contribute to red-ox homeostasis. PRDXs are robustly expressed in various malignancies and critically involved in cell proliferation, differentiation and apoptosis. To elucidate potential role of PRDXs in lymphoma, we studied their expression level in B cell-derived primary lymphoma cells as well as in cell lines. We found that PRDX1 and PRDX2 are upregulated in tumor B cells as compared with normal counterparts. Concomitant knockdown of PRDX1 and PRDX2 significantly attenuated the growth rate of lymphoma cells. Furthermore, in human Burkitt lymphoma cell lines, we isolated dimeric 2-cysteine peroxiredoxins as targets for SK053, a novel thiol-specific small-molecule peptidomimetic with antitumor activity. We observed that treatment of lymphoma cells with SK053 triggers formation of covalent PRDX dimers, accumulation of intracellular reactive oxygen species, phosphorylation of ERK1/2 and AKT and leads to cell cycle arrest and apoptosis. Based on site-directed mutagenesis and modeling studies, we propose a mechanism of SK053-mediated PRDX crosslinking, involving double thioalkylation of active site cysteine residues. Altogether, our results suggest that peroxiredoxins are novel therapeutic targets in Burkitt lymphoma and provide the basis for new approaches to the treatment of this disease

Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo

Photodynamic therapy (PDT) exerts direct cytotoxic effects on tumor cells, destroys tumor blood and lymphatic vessels and induces local inflammation. Although PDT triggers the release of immunogenic antigens from tumor cells, the degree of immune stimulation is regimen-dependent. The highest immunogenicity is achieved at sub-lethal doses, which at the same time trigger cytoprotective responses, that include increased expression of glucose-regulated protein 78 (GRP78). To mitigate the cytoprotective effects of GRP78 and preserve the immunoregulatory activity of PDT, we investigated the in vivo efficacy of PDT in combination with EGF-SubA cytotoxin that was shown to potentiate in vitro PDT cytotoxicity by inactivating GRP78. Treatment of immunocompetent BALB/c mice with EGF-SubA improved the efficacy of PDT but only when mice were treated with a dose of EGF-SubA that exerted less pronounced effects on the number of T and B lymphocytes as well as dendritic cells in mouse spleens. The observed antitumor effects were critically dependent on CD8(+) T cells and were completely abrogated in immunodeficient SCID mice. All these results suggest that GRP78 targeting improves in vivo PDT efficacy provided intact T-cell immune system

Loss of the Orphan Nuclear Receptor SHP Is More Pronounced in Fibrolamellar Carcinoma than in Typical Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) remains a major problem in oncology. The molecular mechanisms which underlie its pathogenesis are poorly understood. Recently the Small Heterodimer Partner (SHP), an orphan nuclear receptor, was suggested to be involved as a tumor suppressor in hepatocellular carcinoma development. To date, there are no such studies regarding fibrolamellar carcinoma, a less common variant of HCC, which usually affects young people and displays distinct morphological features. The aim of our project was to evaluate the SHP levels in typical and fibrolamellar hepatocellular carcinoma with respect to the levels of one of the cell cycle regulators, cyclin D1. We assessed the immunoreactivity levels of SHP and cyclin D1 in 48 typical hepatocellular carcinomas, 9 tumors representing the fibrolamellar variant, 29 non malignant liver tissues and 7 macroregenerative nodules. We detected significantly lower SHP immunoreactivity in hepatocellular carcinoma when compared to non malignant liver tissue. Moreover, we found that SHP immunoreactivity is reduced in fibrolamellar carcinoma when compared to typical hepatocellular carcinoma. We also found that SHP is more commonly lost in HCC which arises in the liver with steatosis. The comparison between the cyclin D1 and SHP expression revealed the negative correlation between these proteins in the high grade HCC. Our results indicate that the impact of loss of SHP protein may be even more pronounced in fibrolamellar carcinoma than in a typical form of HCC. Further investigation of mechanisms through which the loss of SHP function may influence HCC formation may provide important information in order to design more effective HCC therapy

Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20

Jakub Golab and colleagues found that statins significantly decrease rituximab-mediated complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity against B cell lymphoma cells

SAFETY CONTEXT OF CHOSEN PROBLEMS CONCERNING THE SEA TRANSPORT

This paper take chosen aspects related with safety marine transport. It shows chosen features of characteristics of modern marine transports, it discuss some threats and problems concerning affirmation safety unit business